TLR7 and systemic lupus erythematosus: Moreover, the local application of the TLR7/TLR8 receptor agonist resiquimod (R848) has been observed to lead to the development of autoimmune disorders similar to those observed in systemic lupus erythematosus, which is characterized by excessive production of pro-inflammatory cytokines, the production of autoantibodies, and multi-organ damage [134,135].